Compare ESYN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESYN | MDXH |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8M | 18.5M |
| IPO Year | 2022 | 2021 |
| Metric | ESYN | MDXH |
|---|---|---|
| Price | $1.80 | $0.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.13 |
| AVG Volume (30 Days) | 14.6K | ★ 1.2M |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $866,926.00 | N/A |
| Revenue This Year | N/A | $5.10 |
| Revenue Next Year | N/A | $13.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.75 | $0.17 |
| 52 Week High | $2.68 | $5.33 |
| Indicator | ESYN | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 30.86 | 23.92 |
| Support Level | $1.82 | N/A |
| Resistance Level | $2.13 | $0.66 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 24.55 | 8.22 |
EnerSyn Global Inc, formerly HWH International Inc and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore. The Company is presently developing Hapi Marketplace, a business-to-consumer platform featuring diverse product categories, and Hapi Wealth Builder, an educational program focused on wealth-building strategies.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.